Diseases / Malaria
Malaria
DiseaseMalaria is a mosquito-borne parasitic infectious disease caused by Plasmodium species and remains a major global health threat, especially in endemic tropical regions. The WHO African Region carries the overwhelming majority of global malaria burden.
- Trials
- 1130
- Recruiting
- 42
- Completed
- 866
- With results
- 170
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 4 | 1 | — | — | — | 6 |
| Phase 1 | 3 | 5 | — | 2 | 175 | 7 | 7 | — | 9 | 208 |
| Phase 1/2 | 1 | 1 | — | — | 47 | 2 | 1 | — | 3 | 55 |
| Phase 2 | 4 | 2 | — | 1 | 76 | 5 | 5 | — | 4 | 97 |
| Phase 2/3 | — | — | — | — | 19 | 2 | 2 | — | 1 | 24 |
| Phase 3 | 2 | 2 | — | 7 | 113 | 4 | 2 | 1 | 14 | 145 |
| Phase 4 | 6 | 3 | — | — | 111 | 7 | 4 | 2 | 25 | 158 |
| Not applicable | 5 | 6 | — | 8 | 175 | 6 | 6 | 2 | 30 | 238 |
| Unknown | 20 | — | 2 | 2 | 146 | 5 | 5 | — | 19 | 199 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Malaria | 6 | 208 | 55 | 97 | 24 | 145 | 158 | 238 | 199 | 1130 |
| Malaria, Falciparum | 2 | 65 | 20 | 29 | 7 | 30 | 29 | 41 | 44 | 267 |
| Anemia | — | — | — | 1 | — | 10 | 11 | 31 | 9 | 62 |
| Malaria, Vivax | 1 | 6 | 2 | 7 | 1 | 6 | 11 | 9 | 6 | 49 |
| Diarrhea | — | — | — | — | 1 | — | 4 | 17 | 3 | 25 |
| Fever | — | — | — | 2 | — | 1 | 3 | 10 | 8 | 24 |
| Disease | — | — | — | — | — | — | 6 | 9 | 8 | 23 |
| Infections | — | 6 | 1 | 1 | — | 2 | 1 | 2 | 10 | 23 |
| HIV Infections | 1 | 2 | — | — | — | 5 | 6 | 4 | 4 | 22 |
| Pneumonia | — | — | — | — | — | — | 5 | 12 | 2 | 19 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 3 |
| 2 | London School of Hygiene and Tropical Medicine | 104 | 48 |
| 3 | University of Oxford | 76 | 4 |
| 4 | Medicines for Malaria Venture | 53 | 6 |
| 5 | GlaxoSmithKline | 41 | 6 |
| 6 | Centers for Disease Control and Prevention | 31 | 4 |
| 7 | University of California, San Francisco | 30 | 10 |
| 8 | U.S. Army Medical Research and Development Command | 30 | 0 |
| 9 | Sanaria Inc. | 27 | 0 |
| 10 | Novartis Pharmaceuticals | 19 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Artemether, Lumefantrine Drug Combination | 126 |
| 2 | fanasil, pyrimethamine drug combination | 87 |
| 3 | Chloroquine | 57 |
| 4 | Artesunate | 52 |
| 5 | Primaquine | 51 |
| 6 | Amodiaquine | 44 |
| 7 | amodiaquine, artesunate drug combination | 32 |
| 8 | Saline Solution | 26 |
| 9 | Mefloquine | 21 |
| 10 | pyronaridine tetraphosphate, artesunate drug combination | 21 |
Evidence
- Results reported
- 19.6%170 of 866 completed
- Published
- 12.2%106 of 866 completed
- Primary endpoint met
- 17.9%40 of 223 analyses
- Median months to report
- 20
Documents disclosed
Trial profile
- Median enrollment
- 300
- Median duration
- 19months
- Countries
- 73
- Study sites
- 1287
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 21
- Phase 1
- 40
- Phase 1/2
- 43
- Phase 2
- 120
- Phase 2/3
- 217
- Phase 3
- 723
- Phase 4
- 500
- Not applicable
- 1100
- Unknown
- 547
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Bamako | Mali | 63 |
| 2 | Ouagadougou | Burkina Faso | 49 |
| 3 | Kisumu | Kenya | 44 |
| 4 | Kampala | Uganda | 39 |
| 5 | Oxford | United Kingdom | 32 |
| 6 | Lambaréné | Gabon | 30 |
| 7 | Bethesda | United States | 28 |
| 8 | Silver Spring | United States | 22 |
| 9 | Kinshasa | Democratic Republic of the Congo | 21 |
| 10 | Tororo | Uganda | 21 |
Terminations
- Terminated
- 39
- Withdrawn
- 32
- Suspended
- 5
- Stopped for recruitment
- 0.2%2 of 1130 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT07208760 Withdrawn | Withdrawn | After careful review of R21 interaction data that recently became available from a previous L9LS infant study, the study team has made the decision to not move forward with this protocol. | 2029-03-31 |
| NCT07124156 Withdrawn | Withdrawn | Not enough resources | 2026-12-31 |
| NCT05652504 Withdrawn | Withdrawn | Sponsor discontinued development of the investigational vaccine for this protocol and shifted to an alternative investigational product. | 2026-09-14 |
| NCT06804902 Withdrawn | Withdrawn | USAID termination of project funding and activities | 2025-09-30 |
| NCT06805110 Withdrawn | Withdrawn | USAID termination of project funding and activities | 2025-09-30 |
| NCT06122142 Withdrawn | Withdrawn | Funder stop request | 2025-05-31 |
| NCT06225297 Suspended | Suspended | Executive order signed on January 20th 20254 to "reevaluate and realign US foreign aid", resulting in USAID funding freeze | 2025-02-28 |
| NCT04300309 Terminated | Terminated | Sponsor decision | 2024-05-10 |
| NCT02900079 Withdrawn | Withdrawn | delays in obtaining study materials | 2024-03-31 |
| NCT05400746 Terminated | Terminated | Significant delays in vaccine adjuvant supply due to an out of specification within the context of the grant timeline. Limited safety and immunological data could be accrued from incomplete regimens. | 2023-10-19 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: